Nageatte Ibrahim
8PUBLICATIONS
44CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Nov 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.Kenneth F Grossmann, Megan Othus, Sapna P Patel
|Jul 02, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.Georgina V Long, Caroline Robert, Marcus O Butler
|Nov 14, 2020
Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration-Melanoma Research Alliance Public Workshop.Kristen L Mueller, Marc R Theoret, Steven J Lemery
|Sep 18, 2020
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.Alexander M M Eggermont, Christian U Blank, Mario Mandala
|Jul 02, 2020
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.Matteo S Carlino, Alexander M Menzies, Victoria Atkinson
|Jan 26, 2020
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.Jonathan Strosberg, Nobumasa Mizuno, Toshihiko Doi
Pageof 2
Frequent Collaborators
3 joint publications
Caroline Robert
3 joint publications
Georgina V Long
2 joint publications
James Larkin
2 joint publications
Paul C Lorigan
2 joint publications
Andrey Meshcheryakov
2 joint publications
Ralf Gutzmer
2 joint publications
Jean-Jacques Grob
2 joint publications
Antoni Ribas
2 joint publications
Paolo A Ascierto
2 joint publications
Jonathan S Cebon
